Name: ICECURE MEDICAL LTD (ICCM) Stock
Brand: ICECURE MEDICAL LTD
Rating: 3.5 (3 reviews)

ICCM Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: IceCure Medical

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

5 days ago - By: IceCure Medical

IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025

7 days ago - By: IceCure Medical

IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction

11 days ago - By: Zacks Investment Research - Mentions: ACHC

Acadia Healthcare (ACHC) Beats Q3 Earnings and Revenue Estimates

14 days ago - By: IceCure Medical

IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival

a month ago - By: Stocktwits

IceCure Medical’s Treatment For Low-Risk Breast Cancer In Women Aged 70 And Over Receives FDA Approval

3 months ago - By: Benzinga

Examining the Future: Icecure Medical's Earnings Outlook

6 months ago - By: Benzinga

Earnings Preview For Icecure Medical

a month ago - By: IceCure Medical

IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

a month ago - By: IceCure Medical

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care

a month ago - By: IceCure Medical

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

2 months ago - By: IceCure Medical

IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented

2 months ago - By: IceCure Medical

IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented

2 months ago - By: IceCure Medical

IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes

2 months ago - By: IceCure Medical

Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate

3 months ago - By: The Motley Fool

IceCure Medical Advances FDA Review

3 months ago - By: The Motley Fool

IceCure (ICCM) Q2 2025 Earnings Call Transcript

3 months ago - By: Zacks Investment Research - Mentions: CODX

IceCure Medical Ltd. (ICCM) Q2 Earnings Surpass Estimates

3 months ago - By: IceCure Medical

IceCure Reports Financial & Operational Results for the First Half of 2025

3 months ago - By: Zacks Investment Research - Mentions: VTRS

Viatris (VTRS) Tops Q2 Earnings and Revenue Estimates

3 months ago - By: IceCure Medical

IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025

4 months ago - By: IceCure Medical

IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation

4 months ago - By: IceCure Medical

IceCure Announces Commencement of Rights Offering

5 months ago - By: IceCure Medical

IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025

5 months ago - By: IceCure Medical

IceCure Announces Record Date for Rights Offering for Up to $10 Million

5 months ago - By: IceCure Medical

IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes

6 months ago - By: IceCure Medical

IceCure Medical Reports First Quarter 2025 Financial Results

6 months ago - By: IceCure Medical

IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025

6 months ago - By: Zacks Investment Research - Mentions: AAWH

Ascend Wellness Holdings, Inc. (AAWH) Reports Q1 Loss, Misses Revenue Estimates

6 months ago - By: Zacks Investment Research - Mentions: NTRA

Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates

7 months ago - By: IceCure Medical

IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer

7 months ago - By: IceCure Medical

ICECURE MEDICAL LTD (ICCM) Stock News

ICCM Latest News, Press Relases and Analysis

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025

IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction

Acadia Healthcare (ACHC) Beats Q3 Earnings and Revenue Estimates

IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival

IceCure Medical’s Treatment For Low-Risk Breast Cancer In Women Aged 70 And Over Receives FDA Approval

Examining the Future: Icecure Medical's Earnings Outlook

Earnings Preview For Icecure Medical

IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented

IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented

IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes

Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate

IceCure Medical Advances FDA Review

IceCure (ICCM) Q2 2025 Earnings Call Transcript

IceCure Medical Ltd. (ICCM) Q2 Earnings Surpass Estimates

IceCure Reports Financial & Operational Results for the First Half of 2025

Viatris (VTRS) Tops Q2 Earnings and Revenue Estimates

IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025

IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation

IceCure Announces Commencement of Rights Offering

IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025

IceCure Announces Record Date for Rights Offering for Up to $10 Million

IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes

IceCure Medical Reports First Quarter 2025 Financial Results

IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025

Ascend Wellness Holdings, Inc. (AAWH) Reports Q1 Loss, Misses Revenue Estimates

Natera (NTRA) Reports Q1 Loss, Tops Revenue Estimates

IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer

IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium